CD8A and neoplasm: Whereas PDLIM2 nanotherapy increased MHC-I expression on tumor cells (Figure 5B), which is critical for better recognition and killing of tumor cells by CD8+ CTLs, chemotherapy alone or its combination with anti-PD-1 failed to do so (Figure 6D).